Entact Bio is developing enhancement-targeting chimeras (ENTACs) that utilize deubiquitylases to improve the function of critical proteins, addressing issues of protein deficiency, mislocation, and suboptimal activity in various diseases. Their Encompass™ platform enables the identification and optimization of these ENTACs to target previously undruggable pathways and treat complex genetic disorders.
Funding
$40.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases arise from protein dysfunction, including deficiencies, mislocalization, or suboptimal activity. Traditional drug development primarily focuses on inhibiting proteins that contribute to disease, neglecting the potential of enhancing proteins to restore health. This leaves a significant gap in addressing diseases where protein function needs to be improved rather than suppressed.
Solution
Entact Bio is developing Enhancement-Targeting Chimeras (ENTACs), a novel class of orally available, bifunctional small molecules designed to improve the function of critical proteins. ENTACs work by selectively recruiting deubiquitylases (DUBs) to target proteins, leveraging the natural ability of DUBs to enhance protein function through the removal of ubiquitin molecules. This approach aims to restore needed protein levels by extending lifespan, relocate misplaced proteins to their correct cellular location, or modulate protein activity by altering structure or interactions. The company's Encompass™ platform facilitates the identification, validation, and optimization of ENTACs, enabling the targeting of previously undruggable pathways and the treatment of complex genetic disorders and common complex diseases.
Target Audience
Entact Bio's primary target audience includes researchers and clinicians focused on developing treatments for diseases characterized by protein dysfunction, particularly those involving protein deficiencies, mislocalization, or suboptimal activity, as well as patients suffering from these conditions.
Features
- ENTACs: Orally available, bifunctional small molecules that enhance protein function.
- Targets proteins that are deficient, mislocalized, or have suboptimal activity.
- Recruits deubiquitylases (DUBs) to selectively remove ubiquitin molecules.
- Encompass™ platform: An end-to-end system for efficient ENTAC creation.
- Identifies targets amenable to ENTAC intervention.
- Validates ENTAC-disease hypothesis.
- Designs and optimizes target-specific ENTACs.